These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 1979176)

  • 21. Behavioural effects of (+)-4-propyl-9-hydroxynaphthoxazine in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Clarke CE; Boyce S; Sambrook MA; Stahl SM; Crossman AR
    Naunyn Schmiedebergs Arch Pharmacol; 1988 Jul; 338(1):35-8. PubMed ID: 2907097
    [TBL] [Abstract][Full Text] [Related]  

  • 22. N-methyl-D-aspartate receptor antagonist and dopamine D1 and D2 agonist interactions in 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine-induced hemiparkinsonian monkeys.
    Domino EF; Sheng J
    J Pharmacol Exp Ther; 1993 Jan; 264(1):221-5. PubMed ID: 8093726
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Brain α7 nicotinic acetylcholine receptors in MPTP-lesioned monkeys and parkinsonian patients.
    Morissette M; Morin N; Grégoire L; Rajput A; Rajput AH; Di Paolo T
    Biochem Pharmacol; 2016 Jun; 109():62-69. PubMed ID: 27038656
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease.
    Jenner P; Marsden CD
    J Neural Transm Suppl; 1986; 20():11-39. PubMed ID: 3091760
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antiparkinsonian activity of talipexole in MPTP-treated monkeys: in combination with L-dopa and as chronic treatment.
    Irifune M; Nomoto M; Fukuda T
    Eur J Pharmacol; 1994 Oct; 264(2):117-23. PubMed ID: 7851473
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of D1 receptor stimulation in normal and MPTP monkeys.
    Bédard PJ; Boucher R
    Neurosci Lett; 1989 Sep; 104(1-2):223-8. PubMed ID: 2573015
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of chronic treatment of MPTP monkeys with bromocriptine alone or in combination with SKF 38393.
    Rouillard C; Bédard PJ; Di Paolo T
    Eur J Pharmacol; 1990 Aug; 185(2-3):209-15. PubMed ID: 2253695
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antiparkinsonian activity of CY 208-243, a partial D-1 dopamine receptor agonist, in MPTP-treated marmosets and patients with Parkinson's disease.
    Temlett JA; Quinn NP; Jenner PG; Marsden CD; Pourcher E; Bonnet AM; Agid Y; Markstein R; Lataste X
    Mov Disord; 1989; 4(3):261-5. PubMed ID: 2571082
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of LY 171555 and CY 208-243 on tremor suppression in the MPTP monkey model of parkinsonism.
    Gomez-Mancilla B; Boucher R; Bédard PJ
    Mov Disord; 1992; 7(1):43-7. PubMed ID: 1348351
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neuropeptides and dopamine in the marmoset. Effect of treatment with 1-methyl-4-phenyl-1, 2, 3, 6 tetrahydropyridine (MPTP): an animal model for Parkinson's disease?
    Allen JM; Cross AJ; Yeats JC; Ghatei MA; McGregor GP; Close SP; Pay S; Marriott AS; Tyers MB; Crow TJ
    Brain; 1986 Feb; 109 ( Pt 1)():143-57. PubMed ID: 2417654
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of a chronic treatment with an mGlu5 receptor antagonist on brain serotonin markers in parkinsonian monkeys.
    Morin N; Morissette M; Grégoire L; Di Paolo T
    Prog Neuropsychopharmacol Biol Psychiatry; 2015 Jan; 56():27-38. PubMed ID: 25046277
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relative potency and efficacy of some dopamine agonists with varying selectivities for D1 and D2 receptors in MPTP-induced hemiparkinsonian monkeys.
    Domino EF; Sheng J
    J Pharmacol Exp Ther; 1993 Jun; 265(3):1387-91. PubMed ID: 8099621
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The dopamine D1 receptor agonist SKF 38393 suppresses detrusor hyperreflexia in the monkey with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
    Yoshimura N; Mizuta E; Kuno S; Sasa M; Yoshida O
    Neuropharmacology; 1993 Apr; 32(4):315-21. PubMed ID: 8098860
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [A model of Parkinson's disease: effect of L-dopa therapy on movement parameters and electromyographic activity in monkeys treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)].
    Doudet D; Gross C; Lebrun-Grandié P; Bioulac B
    C R Seances Soc Biol Fil; 1985; 179(1):85-97. PubMed ID: 3161601
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Changes of D1 and D2 dopamine receptor mRNA in the brains of monkeys lesioned with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: correction with chronic administration of L-3,4-dihydroxyphenylalanine.
    Morissette M; Goulet M; Calon F; Falardeau P; Blanchet PJ; Bédard PJ; Di Paolo T
    Mol Pharmacol; 1996 Nov; 50(5):1073-9. PubMed ID: 8913337
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quetiapine attenuates levodopa-induced motor complications in rodent and primate parkinsonian models.
    Oh JD; Bibbiani F; Chase TN
    Exp Neurol; 2002 Oct; 177(2):557-64. PubMed ID: 12429201
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of D1 and D2 agonists and antagonists on dyskinesia produced by L-dopa in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys.
    Gomez-Mancilla B; Bédard PJ
    J Pharmacol Exp Ther; 1991 Oct; 259(1):409-13. PubMed ID: 1681090
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effects of chronic levodopa treatment on pre- and postsynaptic markers of dopaminergic function in striatum of parkinsonian monkeys.
    Rioux L; Frohna PA; Joyce JN; Schneider JS
    Mov Disord; 1997 Mar; 12(2):148-58. PubMed ID: 9087972
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Terguride stimulates locomotor activity at 2 months but not 10 months after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment of common marmosets.
    Lange KW; Löschmann PA; Wachtel H; Horowski R; Jähnig P; Jenner P; Marsden CD
    Eur J Pharmacol; 1992 Mar; 212(2-3):247-52. PubMed ID: 1350996
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Opioid antagonists increase the dyskinetic response to dopaminergic agents in parkinsonian monkeys: interaction between dopamine and opioid systems.
    Samadi P; Grégoire L; Bédard PJ
    Neuropharmacology; 2003 Dec; 45(7):954-63. PubMed ID: 14573388
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.